The first experience with angiovit in the combination treatment of acute COVID-19 infection

Abstract

On March 11, 2020, the WHO announced the COVID-19 outbreak a pandemic. The disease was established to be caused by a new single-stranded RNA virus (ss-RNA, 29903 bp) that belongs to a group of coronaviruses (CoV). Objective: to assess the results of a pilot analysis of the efficiency of using Angiovit in the combination treatment of acute COVID-19 with pneumonia or acute respiratory viral infection. Patients and methods. The study enrolled 50 patients with acute COVID-19. In all the patients, the diagnosis of coronavirus infection was confirmed by polymerase chain reaction. Angiovit was used in 25 patients (13 (52%) women) (mean age, 39.4 years) with moderate infection who had been admitted on an average of disease day 3 (a study group). A comparison group consisted of 25 patients whose gender, age, and clinical features of COVID-19 did not differ at the time of admission; they were prescribed only mainstay therapy. Results and discussion. Adding Angiovit to the mainstay therapy contributed to an average reduction in the fever period from 5.88 to 4.12 days (p<0.05) and to the earlier hospital discharge of patients with an improvement (on day 13 versus on day 16.8 days in the comparison group; p<0.05); Normalization of CRP, D-dimer, and homocysteine levels occurred considerably and faster. Conclusion. The pilot study has shown that the use of Angiovit in the combination therapy of COVID-19 reduces the clinical and laboratory manifestations of inflammation and hypercoagulation, which may also be associated with the action of folic acid.